Amneal Pharmaceuticals Inc. (Nasdaq: AMRX) announced certain unaudited preliminary financial results for the second quarter ended June 30, 2025. The company reported net revenue in the range of $720 million to $730 million, marking an approximate 3% increase compared to the same period in 2024. Income before income taxes was between $45 million and $56 million, up from $20 million in the same period in the previous year. Adjusted EBITDA was reported between $180 million and $185 million, representing an approximate 13% increase from the second quarter of 2024. Amneal highlighted significant developments, including the U.S. FDA approval of Brekiya® autoinjector for the treatment of migraine and cluster headache in adults, alongside the strong commercial uptake of CREXONT®. The company also anticipates a BLA submission for a proposed biosimilar to XOLAIR® later in the year. The company noted a decrease in gross leverage to 3.8x and net leverage to 3.7x as of June 30, 2025, attributed to higher profitability and continued debt reduction. Amneal expressed confidence in meeting or exceeding its full-year 2025 guidance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.